Island Pharmaceuticals Limited (ASX:ILA)
Australia
· Delayed Price · Currency is AUD
0.420
+0.005 (1.20%)
At close: Mar 6, 2026
Island Pharmaceuticals Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
| TTM
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
| Operating Revenue | 0.05 | 0.11 | 1.25 | - | - | - | |
| Other Revenue | 0.01 | 0.01 | 0.01 | - | - | - | |
| Revenue | 0.06 | 0.12 | 1.26 | - | - | - | |
| Revenue Growth (YoY) | -84.26% | -90.57% | - | - | - | - | |
| Cost of Revenue | 2.05 | 1.4 | 2.27 | 1.14 | - | - | |
| Gross Profit | -1.99 | -1.29 | -1.01 | -1.14 | - | - | |
| Selling, General & Admin | 2.68 | 2.33 | 1.85 | 1.77 | 1.78 | 2.14 | |
| Research & Development | - | - | - | - | 1.03 | 0 | |
| Operating Expenses | 5.38 | 2.67 | 1.85 | 1.77 | 2.81 | 2.14 | |
| Operating Income | -7.36 | -3.96 | -2.86 | -2.91 | -2.81 | -2.14 | |
| Interest Expense | - | -0.03 | -0.05 | -0.01 | - | - | |
| Interest & Investment Income | 0.17 | 0.06 | 0 | 0.01 | - | - | |
| Currency Exchange Gain (Loss) | -0 | 0 | 0.04 | 0.08 | 0.2 | 0.01 | |
| Pretax Income | -7.2 | -3.92 | -2.86 | -2.83 | -2.61 | -2.13 | |
| Net Income | -7.2 | -3.92 | -2.86 | -2.83 | -2.61 | -2.13 | |
| Net Income to Common | -7.2 | -3.92 | -2.86 | -2.83 | -2.61 | -2.13 | |
| Shares Outstanding (Basic) | 228 | 173 | 90 | 81 | 81 | 19 | |
| Shares Outstanding (Diluted) | 228 | 173 | 90 | 81 | 81 | 19 | |
| Shares Change (YoY) | 88.25% | 91.98% | 11.11% | 0.42% | 334.32% | - | |
| EPS (Basic) | -0.03 | -0.02 | -0.03 | -0.03 | -0.03 | -0.11 | |
| EPS (Diluted) | -0.03 | -0.02 | -0.03 | -0.03 | -0.03 | -0.11 | |
| Gross Margin | - | - | -80.14% | - | - | - | |
| Operating Margin | -11715.94% | -3326.06% | -227.00% | - | - | - | |
| Profit Margin | -11452.57% | -3296.73% | -227.04% | - | - | - | |
| EBIT | -7.36 | -3.96 | -2.86 | -2.91 | -2.81 | -2.14 | |
| EBIT Margin | - | - | -227.00% | - | - | - | |
| Revenue as Reported | 0.23 | 0.18 | 1.27 | 0.01 | - | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.